AnaptysBio (ANAB) Stock Forecast, Price Target & Predictions
ANAB Stock Forecast
AnaptysBio stock forecast is as follows: an average price target of $36.33 (represents a -9.92% downside from ANAB’s last price of $40.33) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
ANAB Price Target
The average price target for AnaptysBio (ANAB) is $36.33 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $47.00 to $30.00. This represents a potential -9.92% downside from ANAB's last price of $40.33.
ANAB Analyst Ratings
According to 8 Wall Street analysts, AnaptysBio's rating consensus is 'Buy'. The analyst rating breakdown for ANAB stock is 0 'Strong Buy' (0.00%), 4 'Buy' (50.00%), 4 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AnaptysBio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 15, 2024 | Joon Lee | Truist Financial | $30.00 | $34.65 | -13.42% | -25.61% |
| Apr 16, 2024 | David Risinger | Leerink Partners | $47.00 | $21.27 | 120.97% | 16.54% |
| Nov 18, 2022 | - | J.P. Morgan | $32.00 | $29.16 | 9.74% | -20.65% |
The latest AnaptysBio stock forecast, released on Aug 15, 2024 by Joon Lee from Truist Financial, set a price target of $30.00, which represents a -13.42% decrease from the stock price at the time of the forecast ($34.65), and a -25.61% decrease from ANAB last price ($40.33).
AnaptysBio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $30.00 | $38.50 |
| Last Closing Price | $40.33 | $40.33 | $40.33 |
| Upside/Downside | -100.00% | -25.61% | -4.54% |
In the current month, the average price target of AnaptysBio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AnaptysBio's last price of $40.33. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 06, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 06, 2024 | Wedbush | Outperform | Outperform | Hold |
| May 10, 2024 | Wells Fargo | Buy | Buy | Hold |
| Mar 12, 2024 | Wedbush | Neutral | Outperform | Upgrade |
| Jan 06, 2023 | Raymond James | Outperform | Market Perform | Downgrade |
| Nov 01, 2022 | Credit Suisse | - | Neutral | Downgrade |
| Nov 01, 2022 | Guggenheim | - | Buy | Upgrade |
| Nov 01, 2022 | Piper Sandler | - | Neutral | Downgrade |
| Nov 01, 2022 | Craig-Hallum | - | Hold | Downgrade |
AnaptysBio's last stock rating was published by Wedbush on Aug 06, 2024. The company gave ANAB a "Buy" rating, the same as its previous rate.
AnaptysBio Financial Forecast
AnaptysBio Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.32M | $3.46M | $1.37M | $6.81M | $1.29M | - | $970.00K | $1.01M | $20.89M | $30.03M | $11.25M | $60.00M | - |
| Avg Forecast | $7.89M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.98M | $7.60M | $7.23M | $6.85M | $7.04M | $6.90M | $22.76M | $4.00M | $3.79M | $2.29M | $2.68M | $2.90M | $5.78M | $13.43M | $5.30M | $5.05M | $976.00K | $6.65M | $28.88M | $9.39M | $80.00M | $2.00M |
| High Forecast | $7.89M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.98M | $7.60M | $7.23M | $6.85M | $7.04M | $9.84M | $22.76M | $4.00M | $4.04M | $2.29M | $2.68M | $2.90M | $5.78M | $13.43M | $5.30M | $8.82M | $1.70M | $11.61M | $50.38M | $16.38M | $139.53M | $3.49M |
| Low Forecast | $7.89M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.50M | $7.98M | $7.60M | $7.23M | $6.85M | $7.04M | $2.61M | $22.76M | $4.00M | $3.46M | $2.29M | $2.68M | $2.90M | $5.78M | $13.43M | $5.30M | $2.94M | $567.44K | $3.87M | $16.79M | $5.46M | $46.51M | $1.16M |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 6 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.45% | 1.29% | 0.47% | 1.18% | 0.10% | - | 0.19% | 1.04% | 3.14% | 1.04% | 1.20% | 0.75% | - |
AnaptysBio's average Quarter revenue forecast for Dec 23 based on 4 analysts is $3.79M, with a low forecast of $3.46M, and a high forecast of $4.04M. ANAB's average Quarter revenue forecast represents a 14.09% increase compared to the company's last Quarter revenue of $3.32M (Sep 23).
AnaptysBio EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 6 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-37.73M | $-40.14M | $-39.92M | $-22.14M | $-26.78M | - | $-30.83M | $-33.60M | $-6.00M | $482.00K | $-18.04M | $33.79M | $-23.63M |
| Avg Forecast | $-6.55M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.63M | $-6.31M | $-6.00M | $-5.69M | $-5.84M | $-5.73M | $-18.89M | $-18.24M | $-3.14M | $-1.90M | $-2.23M | $-19.51M | $-4.80M | $-8.46M | $-4.40M | $-20.86M | $-810.12K | $-9.04M | $809.76K | $-18.82M | $38.41M | $-19.16M |
| High Forecast | $-6.55M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.63M | $-6.31M | $-6.00M | $-5.69M | $-5.84M | $-2.17M | $-18.89M | $-14.59M | $-2.87M | $-1.90M | $-2.23M | $-15.61M | $-4.80M | $-6.77M | $-4.40M | $-16.69M | $-471.00K | $-7.24M | $971.71K | $-15.06M | $46.09M | $-15.33M |
| Low Forecast | $-6.55M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.23M | $-6.63M | $-6.31M | $-6.00M | $-5.69M | $-5.84M | $-8.17M | $-18.89M | $-21.89M | $-3.35M | $-1.90M | $-2.23M | $-23.41M | $-4.80M | $-10.15M | $-4.40M | $-25.04M | $-1.41M | $-10.85M | $647.81K | $-22.59M | $30.73M | $-22.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.86% | 18.02% | 2.05% | 4.61% | 3.17% | - | 1.48% | 41.48% | 0.66% | 0.60% | 0.96% | 0.88% | 1.23% |
2 analysts predict ANAB's average Quarter EBITDA for Sep 21 to be $-9.04M, with a high of $-7.24M and a low of $-10.85M. This is -1976.37% lower than AnaptysBio's previous annual EBITDA (Jun 21) of $482.00K.
AnaptysBio Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 6 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-37.31M | $-39.84M | $-48.45M | $-26.41M | $-37.37M | - | $-40.76M | $-31.09M | $-6.67M | $-429.00K | $-18.16M | $33.65M | $-23.77M |
| Avg Forecast | $-47.89M | $-44.75M | $-42.11M | $-41.18M | $-41.86M | $-41.04M | $-41.19M | $-43.30M | $-45.09M | $-47.83M | $-46.87M | $-47.05M | $-45.34M | $-46.55M | $-28.47M | $-21.45M | $-43.79M | $-48.61M | $-46.38M | $-22.94M | $-26.18M | $-9.40M | $-26.32M | $-24.54M | $-26.32M | $-10.05M | $-720.72K | $-18.95M | $38.25M | $-18.82M |
| High Forecast | $-47.89M | $-44.75M | $-42.11M | $-41.18M | $-41.86M | $-41.04M | $-41.19M | $-43.30M | $-45.09M | $-47.83M | $-46.87M | $-47.05M | $-45.34M | $-42.49M | $-28.47M | $-17.16M | $-38.75M | $-48.61M | $-46.38M | $-18.35M | $-26.18M | $-7.52M | $-26.32M | $-19.63M | $-12.00M | $-8.04M | $-576.58K | $-15.16M | $45.89M | $-15.05M |
| Low Forecast | $-47.89M | $-44.75M | $-42.11M | $-41.18M | $-41.86M | $-41.04M | $-41.19M | $-43.30M | $-45.09M | $-47.83M | $-46.87M | $-47.05M | $-45.34M | $-53.86M | $-28.47M | $-25.74M | $-52.34M | $-48.61M | $-46.38M | $-27.53M | $-26.18M | $-11.28M | $-26.32M | $-29.44M | $-51.78M | $-12.06M | $-864.86K | $-22.74M | $30.60M | $-22.58M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 0.86% | 2.11% | 1.01% | 3.98% | - | 1.66% | 1.18% | 0.66% | 0.60% | 0.96% | 0.88% | 1.26% |
AnaptysBio's average Quarter net income forecast for Mar 21 is $-18.95M, with a range of $-22.74M to $-15.16M. ANAB's average Quarter net income forecast represents a -156.33% decrease compared to the company's last Quarter net income of $33.65M (Dec 20).
AnaptysBio SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 6 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $10.17M | $10.68M | $10.82M | $9.41M | $8.86M | - | $10.20M | $5.39M | $5.43M | $5.25M | $5.42M | $5.09M | $4.79M |
| Avg Forecast | $13.59M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $13.75M | $13.09M | $12.46M | $11.80M | $12.12M | $11.88M | $39.19M | $6.89M | $6.52M | $3.94M | $4.62M | $4.99M | $9.96M | $7.66M | $9.12M | $8.70M | $1.68M | $11.46M | $8.81M | $5.66M | $5.78M | $3.44M |
| High Forecast | $13.59M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $13.75M | $13.09M | $12.46M | $11.80M | $12.12M | $16.95M | $39.19M | $6.89M | $6.96M | $3.94M | $4.62M | $4.99M | $9.96M | $9.19M | $9.12M | $15.18M | $2.93M | $19.99M | $10.58M | $6.79M | $6.94M | $6.01M |
| Low Forecast | $13.59M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $12.92M | $13.75M | $13.09M | $12.46M | $11.80M | $12.12M | $4.50M | $39.19M | $6.89M | $5.96M | $3.94M | $4.62M | $4.99M | $9.96M | $6.13M | $9.12M | $5.06M | $977.16K | $6.66M | $7.05M | $4.53M | $4.63M | $2.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.58% | 2.31% | 2.17% | 0.94% | 1.16% | - | 1.17% | 3.21% | 0.47% | 0.60% | 0.96% | 0.88% | 1.39% |
AnaptysBio's average Quarter SG&A projection for Dec 23 is $6.52M, based on 4 Wall Street analysts, with a range of $5.96M to $6.96M. The forecast indicates a -35.92% fall compared to ANAB last annual SG&A of $10.17M (Sep 23).
AnaptysBio EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | - | 2 | 2 | 6 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.41 | $-1.50 | $-1.73 | $-0.93 | $-1.32 | - | $-1.47 | $-1.13 | $-0.24 | $-0.02 | $-0.66 | $1.23 | $-0.87 |
| Avg Forecast | $-1.75 | $-1.64 | $-1.54 | $-1.51 | $-1.53 | $-1.50 | $-1.51 | $-1.58 | $-1.65 | $-1.75 | $-1.71 | $-1.72 | $-1.66 | $-1.70 | $-1.04 | $-1.57 | $-1.60 | $-1.78 | $-1.70 | $-1.03 | $-0.96 | $-0.62 | $-0.98 | $-0.99 | $-0.99 | $-0.85 | $-0.10 | $-0.69 | $1.94 | $-0.72 |
| High Forecast | $-1.75 | $-1.64 | $-1.54 | $-1.51 | $-1.53 | $-1.50 | $-1.51 | $-1.58 | $-1.65 | $-1.75 | $-1.71 | $-1.72 | $-1.66 | $-1.55 | $-1.04 | $-1.57 | $-1.42 | $-1.78 | $-1.70 | $-1.03 | $-0.96 | $-0.62 | $-0.98 | $-0.45 | $-0.45 | $-0.39 | $-0.05 | $-0.31 | $3.82 | $-0.33 |
| Low Forecast | $-1.75 | $-1.64 | $-1.54 | $-1.51 | $-1.53 | $-1.50 | $-1.51 | $-1.58 | $-1.65 | $-1.75 | $-1.71 | $-1.72 | $-1.66 | $-1.97 | $-1.04 | $-1.57 | $-1.91 | $-1.78 | $-1.70 | $-1.03 | $-0.96 | $-0.62 | $-0.98 | $-1.96 | $-1.95 | $-1.67 | $-0.20 | $-1.35 | $0.89 | $-1.42 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.79% | 0.88% | 1.68% | 0.97% | 2.12% | - | 1.48% | 1.14% | 0.28% | 0.19% | 0.96% | 0.63% | 1.21% |
According to 3 Wall Street analysts, AnaptysBio's projected average Quarter EPS for Mar 21 is $-0.69, with a low estimate of $-1.35 and a high estimate of $-0.31. This represents a -155.96% decrease compared to ANAB previous annual EPS of $1.23 (Dec 20).
AnaptysBio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
| RYTM | Rhythm Pharmaceuticals | $49.62 | $38.33 | -22.75% | Buy |
ANAB Forecast FAQ
Is AnaptysBio a good buy?
Yes, according to 8 Wall Street analysts, AnaptysBio (ANAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 50.00% of ANAB's total ratings.
What is ANAB's price target?
AnaptysBio (ANAB) average price target is $36.33 with a range of $30 to $47, implying a -9.92% from its last price of $40.33. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AnaptysBio stock go up soon?
According to Wall Street analysts' prediction for ANAB stock, the company can go down by -9.92% (from the last price of $40.33 to the average price target of $36.33), up by 16.54% based on the highest stock price target, and down by -25.61% based on the lowest stock price target.
Can AnaptysBio stock reach $60?
ANAB's average twelve months analyst stock price target of $36.33 does not support the claim that AnaptysBio can reach $60 in the near future.
What are AnaptysBio's analysts' financial forecasts?
AnaptysBio's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $30M (high $30M, low $30M), average EBITDA is $-24.901M (high $-24.901M, low $-24.901M), average net income is $-167M (high $-167M, low $-167M), average SG&A $51.66M (high $51.66M, low $51.66M), and average EPS is $-6.119 (high $-6.119, low $-6.119). ANAB's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $30.39M (high $30.39M, low $30.39M), average EBITDA is $-25.227M (high $-25.227M, low $-25.227M), average net income is $-176M (high $-176M, low $-176M), average SG&A $52.34M (high $52.34M, low $52.34M), and average EPS is $-6.431 (high $-6.431, low $-6.431).
Did the ANAB's actual financial results beat the analysts' financial forecasts?
Based on AnaptysBio's last annual report (Dec 2022), the company's revenue was $10.29M, which missed the average analysts forecast of $29.56M by -65.20%. Apple's EBITDA was $-108M, beating the average prediction of $-38.517M by 179.34%. The company's net income was $-129M, beating the average estimation of $-86.434M by 48.93%. Apple's SG&A was $36.64M, beating the average forecast of $35.44M by 3.38%. Lastly, the company's EPS was $-4.57, beating the average prediction of $-3.556 by 28.52%. In terms of the last quarterly report (Sep 2023), AnaptysBio's revenue was $3.32M, beating the average analysts' forecast of $2.29M by 44.98%. The company's EBITDA was $-37.732M, beating the average prediction of $-1.9M by 1886.36%. AnaptysBio's net income was $-37.308M, missing the average estimation of $-48.613M by -23.25%. The company's SG&A was $10.17M, beating the average forecast of $3.94M by 158.11%. Lastly, the company's EPS was $-1.41, missing the average prediction of $-1.777 by -20.65%